Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 19/20 | 0.57 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.57 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.57 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9281459 | 0.93 | DOT1L (0.56) | DOT1LPRMT5PRMT7DNMT1 | |
| SCHEMBL9288530 | 0.85 | DOT1L (0.42) | DOT1LPRMT5PRMT7DNMT1 | |
| SCHEMBL9286361 | 0.85 | CYP1A2 (0.37) | DOT1LPRMT5PRMT7 | |
| SCHEMBL18130000 | 0.84 | CYP1A2 (0.38) | DOT1LPRMT5PRMT7 | |
| SCHEMBL9275685 | 0.83 | DOT1L (0.69) | DOT1LPRMT5PRMT7DNMT1 | |
| SCHEMBL9275688 | 0.83 | DOT1L (0.69) | DOT1LPRMT5PRMT7DNMT1 | |
| Hydrochloric Acid SCHEMBL9278490 | 0.83 | DOT1L (0.69) | DOT1LPRMT5PRMT7DNMT1 | |
| Hydrochloric Acid SCHEMBL9278484 | 0.83 | DOT1L (0.69) | DOT1LPRMT5PRMT7DNMT1 | |
| SCHEMBL9288399 | 0.82 | DOT1L (0.38) | DOT1LPRMT5PRMT7 | |
| SCHEMBL9288392 | 0.82 | DOT1L (0.38) | DOT1LPRMT5PRMT7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11603570-B2 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-03-14 | — | — | US | disclosed |
| US-20200239963-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3027774-B1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10407732-B2 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-09-10 | — | — | US | disclosed |
| US-20160298195-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MEMORIAL SLOAN KETTERING CANCER CENTER | 2016-10-13 | — | — | US | disclosed |
| US-20160251390-A1 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. | 2016-09-01 | — | — | US | disclosed |
| US-9145438-B2 | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2646454-B1 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-8722877-B2 | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20140073597-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130310334-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2646454-A2 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012075500-A2 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073597-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | TPMT, HNMT, EHMT1 | DOT1L 5/4885PRMT5 43/4885PRMT7 41/4885 |
| US-20130310334-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | TPMT, HNMT, EHMT1 | DOT1L 5/4885PRMT5 43/4885PRMT7 41/4885 |
| US-11603570-B2 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition | MLLT1, MCL1, BCR | DOT1L 6/4885PRMT5 1145/4885PRMT7 916/4885 |
| US-10407732-B2 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition | MLLT1, MCL1, BCR | DOT1L 4/4885PRMT5 785/4885PRMT7 655/4885 |
| US-20160251390-A1 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | TPMT, HNMT, EHMT1 | DOT1L 5/4885PRMT5 43/4885PRMT7 41/4885 |
| US-20160298195-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MLLT1, MCL1, BCR | DOT1L 4/4885PRMT5 785/4885PRMT7 655/4885 |
| US-20200239963-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MLLT1, MCL1, BCR | DOT1L 6/4885PRMT5 1145/4885PRMT7 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.